4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid)...